SEC Form 4 · accession 0000880771-17-000032
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 7:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2017 | M | 3,087 | $3.55 | A | 90,613 | D | |
| Common Stock | Mar 6, 2017 | S | 3,087 | $10.297 | D | 87,526 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $3.55 | Mar 6, 2017 | M | 3,087 | D | — | Mar 5, 2020 | Common Stock | 3,087 | 290,400 | D |
| Restricted Stock UnitF4,F5,F6 | — | Mar 8, 2017 | A | 20,000 | A | — | Mar 8, 2027 | Common Stock | 20,000 | 345,000 | D |
| Incentive Stock Option (right to buy)F4,F7 | $9.65 | Mar 8, 2017 | A | 10,843 | A | — | Mar 8, 2027 | Common Stock | 10,843 | 10,843 | D |
| Non-Qualified Stock Option (right to buy)F4,F7 | $9.65 | Mar 8, 2017 | A | 129,157 | A | — | Mar 8, 2027 | Common Stock | 129,157 | 129,157 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F325% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
- F4Granted under the Issuer's 2015 Equity Incentive Plan.
- F5Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F6Vesting for such RSUs will occur 25% on March 8, 2018, 25% on March 8, 2019, 25% on March 8, 2020, and 25% on March 8, 2021, contingent upon the executive's continued employment.
- F725% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.